<DOC>
	<DOCNO>NCT00568542</DOCNO>
	<brief_summary>The study test hypothesis , application low dose erythropoetin beta ( 35 I.E./kg BW/week ) 6 month follow successful coronary revascularization PCI improve leave ventricular remodel assessed cardiac MRI .</brief_summary>
	<brief_title>Chronic , Low Dose Erythropoetin Beta Ischemic Cardiomyopathy</brief_title>
	<detailed_description>Several effect know exerted erythropoetin ( EPO ) directly heart independent hemoglobin level could value immediately revascularization procedure ischemic cardiac remodeling : generation new capillary enhance mobilization endothelial progenitor cell bone marrow . EPO neuron- cardio-protective ischemia/reperfusion . Administration EPO enhance neuronal progenitor differentiate functional neuron ; observation may also valid cardiac compartment . The concept organ-specific effect EPO independent hemoglobin level support analysis EPO analogues lack hematopoietic activity . In human , currently concept test use EPO-doses affect hemoglobin level . The concept valid clinical trial perform show dos low 5000 I.U . EPO weekly increase level endothelial progenitor cell blood . On hand , recent clinical trial also show neutral even deleterious effect high dose EPO treatment raise hemoglobin level 12mg/dl pre-dialysis patient concern cardiovascular endpoint . Therefore , chronic , hemoglobin-neutral administration low dos EPO might successful approach concern ischemic cardiomyopathy . Study outline : This investigator initiate , double-blind , placebo-controlled study test hypothesis , low dos erythropoietin beta ( 35 I.U./kg body weight ) start within 14 day successful percutaneous coronary intervention enhance leave ventricular remodel determined comparison two cardiac MRIÂ´s course 6 month . Secondary endpoint include change diastolic dysfunction measure echocardiography , VO2 measure spiroergometry serum brain natriuretic peptide level .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>successful coronary intervention &lt; 14 day regional contraction deficit leave ventricle detect either echocardiography cardiacMRI globally reduce ejection fraction ( cardiac MRI echocardiography : &lt; 60 % ) willing able cooperate voluntary participation contraindication cardiac MRI ( i.e . pacemaker , ICD current within next 6 month , metal implant ) cardiogenic shock time inclusion uncontrolled hypertension ( systolic blood pressure &gt; 180mmHg ) hemoglobin &gt; 16mg/dl thrombocytosis malignant tumor miss informed consent renal failure ( creatinine &gt; 300 mg/dl ) liver failure prognosis limiting , severe disease ( i.e . dementia ) indication open label erythropoietin treatment allergy towards solvent EPO preparation woman childbearing potential clinical study within precede 30days known alcohol drug abuse neurologic psychiatry disorder previous organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>cardiomyopathy</keyword>
	<keyword>ischemia</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>remodel</keyword>
</DOC>